Lv5
1180 积分 2023-05-29 加入
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease
16天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
29天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
29天前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
1个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
1个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
1个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
1个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
4个月前
已完结
Endothelin Receptor Antagonists in Kidney Disease
4个月前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
4个月前
已关闭
皖公网安备34019202002308
